
    
      Approximately 132 hypercholesterolemic patients already taking statin therapy to treat
      elevated LDL-C will be randomized in a ratio of 1:1:1 to receive either ETC-1002 (120 mg or
      180 mg dose), or placebo for 12 weeks in addition to ongoing statin therapy. This study will
      explore the safety and efficacy of ETC-1002 when given to patients receiving statin therapy.
    
  